地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18771997407
邮箱:sales@amyjet.com

Rieke Metal公司位于美国内布拉斯加州Lincoln市,制造有机卤化锌和聚3-烷基噻吩产品。Rieke Metal提供超过5000种有机金属构件模块及超过40000种精细化学品,并且能够提供定制生产服务。
From the Rieke Metals headquarters in Lincoln, Nebraska, we manufacture the broadest line of organozinc halides and poly-3-alkylthiophenes of any company in the world. We offer over 5,000 organometallic building blocks and over 40,000 fine chemicals with the ability to custom manufacture many more. The Rieke team has over 135 years of shared experience conducting inert atmosphere reactions. Our expertise in creating reliable organozinc and Grignard reagents, fine chemicals, semiconducting polymers is unmatched. It’s no surprise that Rieke Metals has been honored to serve many of the largest and most innovative pharmaceutical and electronics companies in the world.
Rieke Metals公司主要产品:
1000 - Rieke® Highly Reactive Metals
2000 - Rieke® Organozinc Reagents
3000 - Grignard Reagents
4000 - Rieke® Specialty Conducting Polymers
4100 - Substituted Thiophenes
5000 - Functionalized Benzophenones
5500 - Heterocyclic Ketones
6000 - Functionalized Ketones
6250 - Functionalized Benzoylacetonitriles
6500 - Functionalized Trifluoromethyl Ketones
7000 - Functionalized Ketoacids
7500 - Functionalized Ketoesters
8000 - Functionalized Aldehydes and Acetals
8500 - Functionalized Ketoacetals
9000 - 1-Keto-3-Protected Aldehydes
10000 - Functionalized Terminal Alkenes
11000 - Biphenyls (Heterocyclic, Bipyridines, and Pyridyl Phenylamines)
14000 - Alpha-Ketoesters and Acids
18000 - Cyclopentane Dicarboxylic Acids, Anydrides, Ester Acids, and Derivatives
18500 - Cyclohexane Dicarboxylic Acids, Anydrides, Ester Acids, and Derivatives
Novel Chemical Synthesis fine organic compounds
Novel Chemical Synthesis Grignard reagents
Novel Chemical Synthesis organozinc reagents
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Rieke Metals"> Rieke Metals
Premetek公司致力于为学术客户和工业客户提供化学试剂、纳米材料和催化剂,同时也提供多领域的研发服务。通过不断地与业内专业企业进行技术整合,Premetek不断更新产品,并为材料科学和催化领域提供了最多样化和可扩展的选择。
Our retail objectives are to offer the most expansive selection of premium products, provide easy and friendly service, offer the fastest delivery time possible, and ensure that every customer is satisfied with their purchase. Our inventory is determined by extensive market research, attendance at international tradeshows and conferences, customer feedback, and working closely with industry experts and vendors. Premetek is committed to continually improving our services and being the premier online market place for all your needs.
Premetek公司的主要产品包括:
Nanomaterials
Nanomaterial Suspension
Pt,Pd Catalysts -Hydrogenation
Pt,Pd Catalysts -Red/Oxidation
Pt Catalysts - Electrochemistry
Pt Alloy Catalysts - Electrochemistry
Pd Alloy Catalysts - Electrochemistry
Pd,Ru,Ir,Rh,Au Catalysts - Electrochemistry
Fe,Co,Ni,Cu,Ag Catalysts - Electrochemistry
Pt,Pd,Ru,Ir,Rh,Au-Organometallics
Pt, Pd, Rh Homogeneous Catalysts
Custom Products
Special catalysts in stock
| 品名 | 货号 | 规格 |
| Aluminum titanate, Al2TiO5, 40 g each | N10A1000 | 40g |
| Barium strontium titanium oxide, BaSrTi2O6, 40 g each | N10B2000 | 40g |
| Calcium titanate, CaTiO3, 40 g each | N10C1000 | 40g |
| Calcium zirconium titanium oxide, CaZrTi2O3, 40 g each | N10C2000 | 40g |
| Cadmium tungsten oxide, CdWO4, 40 g each | N10C3000 | 40g |
| Cerium aluminate, CeAlO3, 40 g each | N10C4000 | 40g |
| Copper aluminate, CuAl2O4, 40 g each | N10C5000 | 40g |
| Iron nickel oxide, FeNiO4, 40 g each | N10I1000 | 40g |
| Lanthanum chromite, LaCrO3, 40 g each | N10L1000 | 40g |
| Lanthanum manganite , LaMnO3, 40 g each | N10L3000 | 40g |
| Lanthanum substituted lithium titanate, (LaLi3)TiO3, 40 g each | N10L5000 | 40g |
| Lead zirconium substituted titanate, PbZr0.2Ti0.8O3, 40 g each | N10L6000 | 40g |
| Manganese titanate, MnTiO3, 40 g each | N10M1000 | 40g |
| Magnesium aluminate, MgAl2O4, 40 g each | N10M2000 | 40g |
| Nickel cobalt oxide, NiCoO2, 40 g each | N10N1000 | 40g |
| Strontium bismuth niobium oxide, SrBi2Nb2O9, 50 g each | N10S1000 | 40g |
| Strontium ferrite, SrFe12O19, 40 g each | N10S2000 | 40g |
| Yttrium aluminum oxide, Y3Al5O12, 40 g each | N10Y1000 | 40g |
| Yttrium iron oxide, Y3Fe5O12, 40 g each | N10Y2000 | 40g |
| Zinc iron oxide, ZnFe2O4, 40 g each | N10Z1000 | 40g |
| Zinc titanium oxide, ZnTiO3, 40 g each | N10Z2000 | 40g |
| Concentrated Suspension of Nanoscaled Titanium Dioxide (TiO2), 5 kg | N-1000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2000 | 5kg |
| Concentrated Suspension of Nanoscaled Zinc Oxide (ZnO), 5 kg | N-2010 | 5kg |
| Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3000 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3010 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3020 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3130 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3220 | 5kg |
| Concentrated Suspension of Nanoscaled Iron Oxide (Fe2O3), 5 kg | N-3230 | 5kg |
| 0.1% Pt on activated carbon powder, 10 g each | P10J1001 | 10g |
| 0.5% Pt on activated carbon powder, 10 g each | P10J1005 | 10g |
| 1.0% Pt on activated carbon powder, 10 g each | P10J1010 | 10g |
| 5.0% Pt on activated carbon powder, 10 g each | P10J1050 | 10g |
| 10% Pt on activated carbon powder, 10 g each | P10J1100 | 10g |
| 20% Pt on activated carbon powder, 10 g each | P10J1200 | 10g |
| 0.1% Pt on granular carbon, 10 g each | P10J2001 | 10g |
| 0.5% Pt on granular carbon, 10 g each | P10J2005 | 10g |
| 1.0% Pt on granular carbon, 10 g each | P10J2010 | 10g |
| 5.0% Pt on granular carbon, 10 g each | P10J2050 | 10g |
| 0.1% Pd on activated carbon powder, 10 g each | P30J1001 | 10g |
| 0.5% Pd on activated carbon powder, 10 g each | P30J1005 | 10g |
| 1.0% Pd on activated carbon powder, 10 g each | P30J1010 | 10g |
| 5.0% Pd on activated carbon powder, 10 g each | P30J1050 | 10g |
| 10% Pd on activated carbon powder, 10 g each | P30J1100 | 10g |
| 20% Pd on activated carbon powder, 10 g each | P30J1200 | 10g |
| 0.1% Pd on granular carbon, 10 g each | P30J2001 | 10g |
| 0.3% Pd on granular carbon, 10 g each | P30J2003 | 10g |
| 0.5% Pd on granular carbon, 10 g each | P30J2005 | 10g |
| 1.0% Pd on granular carbon, 10 g each | P30J2010 | 10g |
| 5.0% Pd on granular carbon, 10 g each | P30J2050 | 10g |
| 0.5% Pd on alumina spheres, 3 mm, SA= | P30L1005 | 10g |
| 1.0% Pd on alumina spheres, 3 mm, SA= | P30L1010 | 10g |
| 0.1% Pt on alumina powder, 10 g each | P10K1001 | 10g |
| 0.5% Pt on alumina powder, 10 g each | P10K1005 | 10g |
| 1.0% Pt on alumina powder, 10 g each | P10K1010 | 10g |
| 5.0% Pt on alumina powder, 10 g each | P10K1050 | 10g |
| 10% Pt on alumina powder, 10 g each | P10K1100 | 10g |
| 20% Pt on alumina powder, 10 g each | P10K1200 | 10g |
| 0.1% Pd on alumina powder, 10 g each | P30K1001 | 10g |
| 0.5% Pd on alumina powder, 10 g each | P30K1005 | 10g |
| 1.0% Pd on alumina powder, 10 g each | P30K1010 | 10g |
| 5.0% Pd on alumina powder, 10 g each | P30K1050 | 10g |
| 10% Pd on alumina powder, 10 g each | P30K1100 | 10g |
| 20% Pd on alumina powder, 10 g each | P30K1200 | 10g |
| 5% Pt on Vulcan XC-72 | P10A050 | 1g/5g |
| 10% Pt on Vulcan XC-72 | P10A100 | 1g/5g |
| 20% Pt on Vulcan XC-72 | P10A200 | 1g/5g |
| 30% Pt on Vulcan XC-72 | P10A300 | 1g/5g |
| 40% Pt on Vulcan XC-72 | P10A400 | 1g/5g |
| 50% Pt on Vulcan XC-72 | P10A500 | 1g/5g |
| 60% Pt on Vulcan XC-72 | P10A600 | 1g/5g |
| 80% Pt on Vulcan XC-72 | P10A800 | 1g/5g |
| Pt Black, High surface area: 40-50 m2/g, Low density: 0.6-0.9 g/ml | P10V010 | 1g/5g |
| 20% Pt on Durable Carbon | P10D200 | 1g/5g |
| 20% Pt on Vulcan XC-72R | P10B200 | 1g/5g |
| 40% Pt on Vulcan XC-72R | P10B400 | 1g/5g |
| 60% Pt on Vulcan XC-72R | P10B600 | 1g/5g |
| 40% Pt on high surface area Ketjenblack | P10E400 | 1g/5g |
| 50% Pt on high surface area Ketjenblack, | P10E500 | 1g/5g |
| 60% Pt on high surface area Ketjenblack | P10E600 | 1g/5g |
| 70% Pt on high surface area Ketjenblack | P10E700 | 1g/5g |
| 5% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A050 | 1g/5g |
| 10% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A100 | 1g/5g |
| 20% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A200 | 1g/5g |
| 30% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A300 | 1g/5g |
| 40% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A400 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72R | P12B600 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A600 | 1g/5g |
| 80% Pt-Ru (1:1 atomic ratio) on Vulcan XC-72 | P12A800 | 1g/5g |
| Pt-Ru Black (1:1 atomic ratio) | P12V010 | 1g/5g |
| Pt-Ru Black (2.5:1 atomic ratio) | P12V250 | 1g/5g |
| Pt-Ru-Ir Black (1:1:1 atomic ratio) | P124V010 | 1g/5g |
| 50% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E500 | 1g/5g |
| 60% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E600 | 1g/5g |
| 75% Pt-Ru (1:1 atomic ratio) on Ketjenblack | P12E750 | 1g/5g |
| 20% Pt-Pd (1:3 atomic ratio) on Vulcan XC-72 | P13A203 | 1g/5g |
| 20% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A200 | 1g/5g |
| 20% Pt-Pd (3:1 atomic ratio) on Vulcan XC-72 | P13A230 | 1g/5g |
| 40% Pt-Pd (1:1 atomic ratio) on Vulcan XC-72 | P13A400 | 1g/5g |
| Pt-Pd Black (1:1 atomic ratio) | P13V010 | 1g/5g |
| Pt-Rh Black (1:1 atomic ratio) | P15V010 | 1g/5g |
| 20% Pt-Ir (1:3 atomic ratio) on Vulcan XC-72 | P14A203 | 1g/5g |
| 20% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A200 | 1g/5g |
| 20% Pt-Ir (3:1 atomic ratio) on Vulcan XC-72 | P14A230 | 1g/5g |
| 40% Pt-Ir (1:1 atomic ratio) on Vulcan XC-72 | P14A400 | 1g/5g |
| Pt-Ir Black (1:1 atomic ratio) | P14V010 | 1g/5g |
| 20% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA230 | 1g/5g |
| 40% Pt-Cr (3:1 atomic ratio) on Vulcan XC-72 | P1AA430 | 1g/5g |
| 20% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA200 | 1g/5g |
| 40% Pt-Fe (1:1 atomic ratio) on Vulcan XC-72 | P1BA400 | 1g/5g |
| 40% Pt-Fe (3:1 atomic ratio) on Vulcan XC-72 | P1BA430 | 1g/5g |
| 20% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA200 | 1g/5g |
| 20% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA230 | 1g/5g |
| 40% Pt-Co (1:1 atomic ratio) on Vulcan XC-72 | P1CA400 | 1g/5g |
| 40% Pt-Co (3:1 atomic ratio) on Vulcan XC-72 | P1CA430 | 1g/5g |
| 60% Pt-Co (3:1 atomic ratio) on Ketjenblack | P1CE630 | 1g/5g |
| 20% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA200 | 1g/5g |
| 20% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA230 | 1g/5g |
| 40% Pt-Ni (1:1 atomic ratio) on Vulcan XC-72 | P1DA400 | 1g/5g |
| 40% Pt-Ni (3:1 atomic ratio) on Vulcan XC-72 | P1DA430 | 1g/5g |
| 60% Pt-Ni (3:1 atomic ratio) on Ketjenblack | P1DE630 | 1g/5g |
| 20% Pt-Cu (1:1 atomic ratio) on Vulcan XC-72 | P1EA200 | 1g/5g |
| 20% Pt-Cu (3:1 atomic ratio) on Vulcan XC-72 | P1EA230 | 1g/5g |
| 20% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA230 | 1g/5g |
| 40% Pt-Sn (3:1 atomic ratio) on Vulcan XC-72 | P1FA430 | 1g/5g |
| 20% Pd-Ir (1:3 atomic ratio) on Vulcan XC-72 | P34A203 | 1g/5g |
| 20% Pd-Ir (1:1 atomic ratio) on Vulcan XC-72 | P34A200 | 1g/5g |
| 20% Pd-Ir (3:1 atomic ratio) on Vulcan XC-72 | P34A230 | 1g/5g |
| 20% Pd-Rh (1:1 atomic ratio) on Vulcan XC-72 | P35A200 | 1g/5g |
| 20% Pd-Rh (3:1 atomic ratio) on Vulcan XC-72 | P35A230 | 1g/5g |
| 20% Pd-Ni (1:1 atomic ratio) on Vulcan XC-72 | P3DA200 | 1g/5g |
| 40% Pd-Au (1:1 atomic ratio) on Ketjenblack | P13E400 | 1g/5g |
| 5% Pd on Vulcan XC-72 | P30A050 | 1g/5g |
| 10% Pd on Vulcan XC-72 | P30A100 | 1g/5g |
| 20% Pd on Vulcan XC-72 | P30A200 | 1g/5g |
| 40% Pd on Vulcan XC-72 | P30A400 | 1g/5g |
| 40% Pd on Ketjenblack | P30E400 | 1g/5g |
| 60% Pd on Vulcan XC-72 | P30A600 | 1g/5g |
| 80% Pd on Vulcan XC-72 | P30A800 | 1g/5g |
| Pd Black, High surface area 40~48 m2/g | P30V010 | 1g/5g |
| 20% Ru on Vulcan XC-72 | P20A200 | 1g/5g |
| 40% Ru on Vulcan XC-72, | P20A400 | 1g/5g |
| Ru Black, High surface area 38~48 m2/g | P20V010 | 1g/5g |
| RuO2 powder, Surface area 18-25 m2/g | P20V020 | 1g/5g |
| 5% Ir on Vulcan XC-72 | P40A050 | 1g/5g |
| 10% Ir on Vulcan XC-72 | P40A100 | 1g/5g |
| 20% Ir on Vulcan XC-72 | P40A200 | 1g/5g |
| 40% Ir on Vulcan XC-72 | P40A400 | 1g/5g |
| Ir Black, High Surface area, 55~65 m2/g, | P40V010 | 1g/5g |
| IrOx powder, conductive, SA:10-20 m2/g | P40V020 | 1g/5g |
| Ru-Ir Black (1:1 atomic ratio) | P24V010 | 1g/5g |
| 20% Rh on Vulcan XC-72 | P50A200 | 1g/5g |
| Rh Black, High surface area 40~50 m2/g | P50V010 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: 4-8 nm) | P60N200 | 1g/5g |
| 20% Au on Vulcan XC-72 (Au particle size: ~25 nm) | P60A200 | 1g/5g |
| 30% Au on Vulcan XC-72 (Au particle size: 8 nm) | P60N300 | 1g/5g |
| 40% Au on Vulcan XC-72 (Au particle size: ~35 nm) | P60A400 | 1g/5g |
| 40% Au on Ketjenblack (Au particle size: 4 nm) | P60E400 | 1g/5g |
| 60% Au on Vulcan XC-72 (Au particle size: ~45 nm) | P60A600 | 1g/5g |
| 5% Fe on Vulcan XC-72 | T10A050 | 1g/5g |
| 10% Fe on Vulcan XC-72 | T10A100 | 1g/5g |
| 20% Fe on Vulcan XC-72 | T10A200 | 1g/5g |
| 1% Co on Vulcan XC-72 | T20A010 | 1g/5g |
| 5% Co on Vulcan XC-72 | T20A050 | 1g/5g |
| 10% Co on Vulcan XC-72 | T20A100 | 1g/5g |
| 20% Co on Vulcan XC-72 | T20A200 | 1g/5g |
| 1% Ni on Vulcan XC-72 | T30A010 | 1g/5g |
| 5% Ni on Vulcan XC-72 | T30A050 | 1g/5g |
| 10% Ni on Vulcan XC-72 | T30A100 | 1g/5g |
| 20% Ni on Vulcan XC-72 | T30A200 | 1g/5g |
| 40% Ni on Vulcan XC-72 | T30A400 | 1g/5g |
| 1% Cu on Vulcan XC-72 | T40A010 | 1g/5g |
| 5% Cu on Vulcan XC-72 | T40A050 | 1g/5g |
| 10% Cu on Vulcan XC-72 | T40A100 | 1g/5g |
| 20% Cu on Vulcan XC-72 | T40A200 | 1g/5g |
| 40% Cu on Vulcan XC-72 | T40A400 | 1g/5g |
| 60% Cu on Vulcan XC-72 | T40A600 | 1g/5g |
| 20% Ag on Vulcan XC-72 | P70A200 | 1g/5g |
| 40% Ag on Vulcan XC-72 | P70A400 | 1g/5g |
| 60% Ag on Vulcan XC-72 | P70A600 | 1g/5g |
| 80% Ag on Vulcan XC-72 | P70A800 | 1g/5g |
| Platinum (II) acetylacetonate, 5 g each | P10H110 | 5g |
| (1,5-Cyclooctadiene)dimethylplatinum(II), 1 g each | P10H120 | 1g |
| Dichloro(1,5-cyclooctadiene)platinum(II), 5 g each | P10H130 | 5g |
| Diphenyl(1,5-cyclooctadiene)platinum(II), 5 g each | P10H140 | 5g |
| Trimethylbenzylammoniumhexachloroplatinate (IV), 1 g each | P10H150 | 1g |
| Palladium(II) acetylacetonate, 5 g each | P30H110 | 5g |
| Dichloro(1,5-cyclooctadiene)palladium(II), 5 g each | P30H120 | 5g |
| Hermann's Catalyst, 5 g each | P30H130 | 5g |
| 1,1'-Bis(di-tert-butylphosphino)ferrocene palladium dichloride, 1 g each | P30H140 | 1g |
| Bis(dibenzylideneacetone)palladium(0), 5 g each | P30H150 | 5g |
| Palladium(0) tetrakis(triphenylphosphine), 5 g each | P30H160 | 5g |
| Ruthenium(III) acetylacetonate, 5 g each | P20H110 | 5g |
| Dichloro(1,5-cyclooctadiene)ruthenium(II), polymer, 5 g each | P20H120 | 5g |
| Bis(cyclopentadienyl)ruthenium, 5 g each | P20H130 | 5g |
| Irridium(III) acetylacetonate, 5 g each | P40H110 | 5g |
| Chloro(1,5-cyclooctadiene)iridium(I) dimer, 5 g each | P40H120 | 5g |
| Rhodium(III) acetylacetonate, 5 g each | P50H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 1 g each | P50H120 | 1g |
| Chloro(triphenylphosphine)gold(I), 5 g each | newitem3 | 5g |
| Bromo(triphenylphosphine)gold(I), 5 g each | P60H110 | 5g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Chloro(1,5-cyclooctadiene)rhodium(I) dimer, 98% 1 g | P50-002 | 1g |
| Doyledirhodium catalyst-Rh2(5R-MPPIM)4, 1 g | P50-001 | 1g |
| Doyledirhodium catalyst-Rh2(5S-MPPIM)4, 1 g | P50-003 | 1g |
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Prozyme公司位于美国加州,为广大客户提供诊断和科研所需的标记物、蛋白质与酶。Prozyme 于2003年1月收购了Glyko®产品线,包括研究糖类的酶及相关试剂。其中也包括Glyko®于1999年收购的Oxford GlycoSciences,Ltd 公司生化试剂产品线。
ProZyme is now a part of Agilent Technologies, Inc.
ProZyme, Inc. was founded in 1990 with a vision of establishing a high-quality, value-added and customer-driven biochemical reagent company. We are proud to continue to provide the highest level of products, services and support to our customers at large and small biotechnology, biopharmaceutical and academic institutions across the world.
ProZyme公司产品系列:
(1)糖生物学研究工具(Glyko.系列)
(2)PhycoLink. 荧光结合试剂( 抗体/ 蛋白标记) PE, PerCP conjugates, BPE conjugates, CPC conjugates,生物素,纯化试剂盒,结合试剂盒,标记二抗
(3)PhycoLink.纯化与标记试剂盒/ Purification and Conjugation Kits
(4) PhycoProTM 藻胆蛋白/ Phycobiliproteins
(5)生物素结合蛋白/ Biotin-binding Proteins 链亲和素
(6)固定化链亲和素/ Immobilized Streptavidin 琼脂糖-链亲和素
(7))链亲和素结合物/ Streptavidin Conjugates 链亲和素- AP,链亲和素- HRP
(8) Marker Enzyme 半乳糖苷酶
(9)位点特异性蛋白酶/ Site-specific Protease Factor Xa (lyophilized)
(10)客户定制结合服务或其他
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理Aalto Bio Reagents品牌。
Aalto Bio Reagents 是一家专注于为诊断、疫苗和生物制药行业提供高质量生物试剂和原料的公司,提供病毒、细菌、激素、人源蛋白、肿瘤标志物、传染病的抗原和抗体。Aalto Bio Reagents 的产品广泛应用于传染病诊断、疫苗开发、生物制药和科学研究等领域。主要业务包括:
(1)诊断试剂原料:Aalto Bio Reagents 提供用于体外诊断(IVD)的生物试剂,包括抗原、抗体、血清和质控品。这些试剂支持传染病(如 HIV、肝炎、流感)、自身免疫疾病和癌症的诊断。
(2)疫苗开发原料:提供用于疫苗开发的生物原料,如病毒抗原、重组蛋白和佐剂。
(3)生物制药原料:Aalto Bio Reagents 提供用于生物制药生产的生物原料,如细胞培养添加剂、纯化试剂和分析标准品。这些原料支持单克隆抗体、重组蛋白和其他生物药物的生产。
(4)GMP 生产:Aalto Bio Reagents拥有符合 GMP(药品生产质量管理规范)标准的生产设施,能够为诊断、疫苗和生物制药行业提供高质量的生物原料。
<<<< " data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Aalto Bio Reagents品牌"> 艾美捷科技代理Aalto Bio Reagents品牌


艾美捷科技代理Advansta全系列Western Blot试剂及分子生物学试剂。
Advansta成立于2005年,位于美国加州Menlo Park,主要研发和生产蛋白定性&定量试剂,这些产品在实验中表现优异、操作简单便捷。产品主要包括荧光Western Blot试剂、化学发光Western Blot试剂、ELISA试剂盒、电泳试剂、抗体及抗体标记产品、样品制备试剂、蛋白纯化试剂、蛋白染色试剂、缓冲液及蛋白鉴定服务等。
Founded in 2005 and headquartered in Menlo Park, California, Advansta accelerates life science research by developing and supplying novel protein characterization tools that offer superior performance, simplicity,and convenience. With over 200 citations in 2014 alone, our flagship products have become recognized as the most sensitive chemiluminescent substrates on the market.
产品包括:
Fluorescent Western blotting
Chemiluminescent Western blotting
ELISA
Electrophoresis
Antibodies and antibody labeling
Sample preparation
Purification
Protein staining
Buffers and solutions
Custom services
" data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Advansta"> Advansta
INDOOR Biotechnologies公司专注于室内空气品质、环境科学、过敏和哮喘相关的检测用产品和服务。
Indoor Biotechnologies was founded by Dr. Martin D. Chapman, formerly Professor of Medicine and Microbiology at the University of Virginia and a member of the UVA Asthma and Allergic Diseases Center. Dr. Chapman is a Fellow of the American Academy of Allergy, Asthma and Immunology and has served as a consultant to the U.S. National Institutes of Health, the Environmental Protection Agency, academic institutions and Fortune 500 companies..
INDOOR Biotechnologies公司的主要产品包括:
Multiplex IgE-QBA™ Kits
MARIA® Kits
ELISA Kits
Purified Allergens
Molecular Reference Standards
Antibodies
Rhinovirus Products
Allergen Standards
RhinixPRO Nasal Filters
Rapid Test and Dust Collection
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://bio-helix.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="INDOOR Biotechnologies"> INDOOR Biotechnologies
艾美捷科技代理ADS Biotec核酸色谱柱系列产品,用于RNA、DNA的分离和纯化。
RNASep™ 和DNASep™ 柱由均匀的烷基化无孔或大孔聚苯乙烯-二乙烯基苯(PS-DVB)共聚物微球组成,提供优异的分辨率和优异的灵敏度。
柱可以与大多数HPLC系统一起使用,以实现一致的性能和更快的纯度评估。

OligoSep™ HC Cartridge – High Capacity Oligonucleotide Separation Column
货号:NUC-99-3560
![]()

RNASep™ Semi-Prep – Ultra High Capacity RNA Purification Column
货号:RPC-99-3015
![]()

RNASep™ Semi-Prep – High Capacity RNA Purification Column
货号:RPC-99-2110
![]()

RNASep™ Prep – RNA Purification Column
货号:RNA-99-3810
![]()

OligoSep™ Prep HC Cartridge – High Capacity Oligonucleotide Purification Column
货号:NUC-99-3860
![]()

OligoSep™ Cartridge – Oligonucleotide Analysis Column
货号:NUC-99-3550
![]()

DNASep™ HT Cartridge – High Throughput DNA Separation Column
货号:DNA-99-3710
![]()

DNASep™ Cartridge – DNA Separation Column
货号:DNA-99-3510
![]()

艾美捷科技代理代理MYOCEA品牌产品。
MYOCEA是一家专注于肌肉生物学和细胞培养技术的公司,致力于为科研和工业应用提供创新的肌肉细胞模型和相关产品。MYOCEA 以其独特的MyoCells™技术平台而闻名,该平台能够生成高度功能化的肌肉细胞,广泛应用于药物开发、毒理学测试、食品科学和再生医学等领域。MyoCells™技术平台能够生成与体内肌肉细胞高度相似的体外模型,为研究肌肉生物学和相关疾病提供了强大的工具。MYOCEA主要产品和技术包括:
(1)MyoCells™ 平台
MyoCells™ 肌肉细胞,高度功能化的肌肉细胞,具有与体内肌肉相似的生理特性。
MyoCells™ 培养基,专为肌肉细胞优化,支持细胞生长和功能维持。
MyoCells™ 试剂盒,包含细胞、培养基和实验指南,方便用户快速开展实验。
(2)药物开发工具
肌肉毒性测试,用于评估药物对肌肉细胞的毒性。
肌肉功能分析,提供高灵敏度的收缩性和代谢活性检测工具。
个性化药物筛选,基于患者来源的肌肉细胞模型,支持个性化医疗研究。
(3)食品科学应用
细胞培养肉研究,提供高质量的肌肉细胞,用于细胞培养肉开发。
食品添加剂测试,用于评估食品添加剂对肌肉细胞的影响。
(4)再生医学工具
肌肉再生研究,提供肌肉细胞模型,用于研究肌肉再生和修复机制。
组织工程,支持肌肉组织工程和生物材料开发。
(5)定制服务
定制肌肉细胞模型,根据客户需求开发特定的肌肉细胞模型。
合同研究服务(CRO),提供从实验设计到数据分析的全流程服务。

Lumiprobe Corporation是美国一家高品质生物技术公司,专业提供分子生物学研究用的活性荧光染料。从2006年开始,Lumiprobe公司生产并销售生命科学研究和诊断学应用的优质化学药品。产品主要有:活性染料(Reactive Dye)和SYBR Green I 染料,用于寡核苷酸合成的亚磷酰胺,点击化学和其它试剂。
Since 2006, we manufacture and sell advanced chemicals for life science research, and diagnostics. Our catalog includes fluorescent dyes, phosphoramidites for oligonucleotide synthesis, Click chemicals, and other reagents. Most of the items are kept in stock, and ready for immediate shipping to worldwide locations.
主要产品有:
(1)Reactive dyes
Dye NHS esters
Dye azides
Dye alkynes
Dye maleimides
Dye hydrazides
Carboxylic acids
Amino dyes
Tetrazines
Cycloalkyne dyes
Miscellaneous dyes
(2)Click Chemistry reagents
Non-fluorescent azides
Non-fluorescent alkynes
(3)DNA
PCR/qPCR
Modified triphosphates
Phosphoramidites
CPG solid supports
(4)Miscellaneous reagents
Bifunctional crosslinkers
Auxiliary reagents
Proteomic reagents
(5)Pegylation & PEG Linkers
(6)Ready-to-use kits
Protein labeling kits
PCR/qPCR
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:18327026838
邮箱:sales@amyjet.com
0.3644